[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Niguarda Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":632},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,47,74,99,125,149,183,206,232,257,282,307,329,347,372,391,418,445,472,494,518,540,564,584,604],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644162","artificial-voice-analysis-and-telemonitoring-for-heart-failure-a-feasibility-study-100644162",false,"NCT07664748","Artificial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility Study","AVATAR-HF (Artificial Voice Analysis and Telemonitoring for Heart Failure): Studio di fattibilità Sull'Uso Dell'Analisi Vocale Basata su Intelligenza Artificiale Per il Telemonitoraggio Dei Pazienti Con Insufficienza Cardiaca.","AVATAR-HF","Inclusion Criteria\n\n* Age ≥ 18 years\n* Diagnosis of heart failure (NYHA Class II-IV), according to the Diagnosis Related Group (DRG) classification.\n* Recent discharge following acute heart failure (AHF) or ongoing treatment with Levosimendan in a Day Hospital setting.\n* Provision of signed informed consent in Italian.\n* Currently receiving Guideline-Directed Medical Therapy (GDMT) for heart failure\n\nExclusion Criteria:\n\n* Inability or incapacity to provide informed consent.\n* Cognitive impairment severe enough to prevent interaction with the avatar and compromise the reliability of the collected data.\n* Significant phonation disorders (e.g., results of previous otorhinolaryngological surgery or post-traumatic outcomes).\n* Inability to manage a compatible device or the device provided by the study for interaction with the AVATAR-SC platform.\n* Life expectancy of less than 6 months due to concurrent comorbidities.\n* Technological or language barriers.","ALL","18 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Heart failure is a serious condition and a major reason why older adults are admitted to the hospital. Even after going home, many patients struggle to get the follow-up care they need, leading to high rates of return to the hospital.\n\nWhile remote monitoring technology exists, it is often difficult to use, expensive, or hard for doctors to interpret.\n\nRecent research suggests that changes in a person's voice and speech can be early warning signs of worsening heart failure, but we need to test if this can work reliably in a home setting.This study tests a new, user-friendly platform called AVATAR-SC.\n\nThis system uses a a computer-generated character to interact with patients. By analyzing short voice clips and simple health questionnaires provided by the patient, the system aims to make home monitoring easier and more effective.\n\nThe study will involve 60 participants divided into two groups:half of the patients who have recently been discharged from the hospital following a heart failure episode; the other 30 patients who visit the hospital monthly for a specific heart failure treatment (Levosimendan).\n\nParticipants will interact with the digital avatar twice a week. During these sessions, they will provide brief voice recordings and answer a few questions about how they feel. It is important to note that the AI in this study is not making medical decisions or changing the patient's current treatment; it is strictly being tested to see how well the technology functions.\n\nAs a feasibility study, the primary goal is to evaluate the practical implementation of the technology rather than clinical outcomes.\n\nThe research focuses on: Determining if patients can navigate the system easily and independently, Assessing how consistently participants engage with the scheduled sessions, Verifying the technical reliability of the platform in a home environment,identifying the strengths and challenges of the system to prepare for future, larger-scale trials.\n\nBenefits: Participants may feel more supported and more aware of their symptoms through regular check-ins.\n\nRisks: The risks are very low. They mostly involve getting used to new technology and ensuring that personal data is kept private and secure.\n\nImpact If successful, AVATAR-SC could lead to a new way for doctors to keep an eye on heart failure patients at home, catching problems early through the sound of their voice and preventing unnecessary hospital visits.",[28],"Heart Failure",[30,31,32,33],"Vocal biomarkers","Artificial Intelligence","Feasibility Study","Neuropsychological and Psychological Test","NOT_YET_RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":22},"2026-06-30",{"date":42,"type":22},"2028-05-15",{"name":44,"class":45},"Niguarda Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100639946","transplantation-vs-resection-after-conversion-therapy-for-initially-unresectable-colorectal-liver-metastases-100639946","NCT07607873","TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases","TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable","TRANSECT","Inclusion Criteria screening phase (before randomization):\n\n* Signed screening phase informed consent.\n* Age \\>18.\n* Performance status score of Eastern Cooperative Oncology Group (PS-ECOG) 0-1\n* Adequate organ functions.\n* Liver-limited Metastatic Disease Confirmed as Unresectable by Colorectal Oncology Multidisciplinary Tumor Board (MTB).\n* Histologically documented adenocarcinoma of the colon or intra-peritoneal rectum\n* Absence of extra-hepatic disease demonstrated by contrast-enhanced CT + MRI and, in clinically indicated (clinical suspicion or elevated biomarkers), FDG-PET.\n* No previous systemic treatment for unresectable disease.\n* No previous systemic treatment for primary tumor resection\n* Recurrence occurring beyond six months after completion of adjuvant treatment.\n* MMR proficient cancer (MSS) regardless of RAS mutational status, BRAF-WT except for BRAF V600E-mut treated and responding to anti-BRAF + cytotoxic therapy.\n\nExclusion criteria:\n\n* Absolute contraindication to liver transplant.\n* Other malignancies in the previous 5 years excluding non melanoma skin-cancers or in situ disease.\n* Hereditary CRC syndromes including FAP and Lynch syndrome.\n* Previous extrahepatic metastatic localization or locoregional tumor recurrence.\n* Extra-peritoneal cancers.\n* BRAFV600E-mut patients non-responder to 1st line anti-BRAF + cytotoxic therapy (Elez et al NEJM 2025, ref. 8)\n\nRandomization inclusion criteria:\n\n* Signed randomization phase informed consent.\n* CEA \\\u003C 80 ng\u002Fml or decrease in CEA level at least 50% from baseline (TRANSMET criteria (5)).\n* Conversion to resectability according to MTB discussion during first 6 months of induction chemotherapy.\n* Sustained objective response defined as stable disease (SD), partial response (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria (19), under chemotherapy, for at least 3 months.\n* Surgical resection of the primary tumor with a high oncological standard, as outlined in The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer (20), ensuring safe margins of resection and adequate TNM staging.\n* Histologically confirmed primary tumor staged as pT4a and\u002For pN2, with achievement of R0 resection. In patients with pT4a and\u002For pN2 disease, only metachronous metastases are eligible. For pT4a tumors, a minimum disease-free interval of 6 months from primary tumor resection is required before randomization.\n* Time from primary resection to liver transplantation or radical local treatment \\>6 months\n* Absence of local recurrence and extra-hepatic disease demonstrated by contrast-enhanced CT + MRI and, in clinically indicated (clinical suspicion or elevated biomarkers), FDG-PET.\n* PS-ECOG 0-1. Adequate organ functions.",{"count":56,"type":22},70,[25],"The TRANSECT trial is a prospective randomized study designed to evaluate the role of liver transplantation (LT) versus radical local treatment (hepatic resection and\u002For ablation) in patients with initially unresectable colorectal liver metastases (CRLM) converted to resectability after conversion therapy.\n\nLiver metastases are the leading cause of mortality in colorectal cancer patients. Although hepatic resection combined with chemotherapy remains the standard curative-intent treatment, only a minority of patients are eligible for upfront surgery. Advances in modern conversion chemotherapy have substantially increased the proportion of patients who can subsequently undergo curative local treatment. However, liver resection after intensive chemotherapy is still associated with high rates of intrahepatic recurrence, risk of R1 resections, chemotherapy-induced liver injury, and the need for complex surgical procedures carrying considerable morbidity and mortality. In parallel, recent studies investigating LT for unresectable CRLM, including the TRANSMET trial, demonstrated highly promising oncological outcomes, with 5-year overall survival rates exceeding 50% in selected patients.\n\nBased on these findings, the TRANSECT trial hypothesizes that LT may represent a more effective therapeutic strategy also in patients initially deemed unresectable but subsequently converted to resectability, by completely removing the hepatic metastatic niche.\n\nTRANSECT is a single-center, randomized, open-label, proof-of-concept trial. Patients with liver-only CRLM initially assessed as unresectable by a dedicated multidisciplinary tumor board and subsequently converted to resectability after systemic therapy will be randomized to either LT or hepatic resection and\u002For ablation. The primary endpoint is 3-year intention-to-treat overall survival (OS). Secondary endpoints include perioperative morbidity and mortality, disease-free survival, treatment adherence, quality of life, and exploratory translational analyses including radiomics and circulating tumor DNA assessment.\n\nA total of 70 patients (35 per arm) will be enrolled, with an estimated overall study duration of 5 years. TRANSECT represents the first randomized trial directly comparing LT and liver-directed surgery in patients with initially unresectable CRLM converted to resectability after systemic therapy, with the aim of redefining curative treatment strategies in this selected patient population.",[60],"Colorectal Liver Metastases",[62,60,63,64,65],"Liver Transplantation","Conversion Therapy","Liver Resection","Randomized Controlled Trial","2026-05-22",{"date":68,"type":38},"2026-05-26",{"date":70,"type":22},"2026-06-15",{"date":72,"type":22},"2031-06-15",{"name":44,"class":45},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100385172","altshock-2-registry-100385172","NCT04295252","Altshock-2 REGISTRY","Cardiogenic Shock: a Prospective National Registry to Get Insights in Patients' Profile, Management and Outcome","All consecutive CS patients hospitalized in the above reported centres between January 2020 and December 2030.\n\nCardiogenic shock is defined as:\n\n1. Systolic blood pressure (SBP) \\\u003C90 mmHg or mean arterial pressure (MAP) \\\u003C60 mmHg, after an appropriate fluid challenge if there is no sign of overt fluid overload, OR need of vasoactive agents to maintain SBP \\> 90 mmHg or MAP \\> 60 mmHg, OR need of MCS;\n2. At least one of the following criteria\u002Fsigns of overt hypoperfusion: mixed venous oxygen saturation \\\u003C60%; arterial lactates \\> 2 mmol\u002FL; oliguria \\\u003C 0.5 ml\u002FKg\u002Fh for at least 6 hours.",{"count":82,"type":22},3000,"1 Day","OBSERVATIONAL","The study will provide data on profile, management, outcome, and evolution over time of cardiogenic shock patients admitted to the Intensive Coronary Care Units",[87],"Cardiogenic Shock",[89],"cardiogenic shock","RECRUITING","2026-05-13",{"date":93,"type":38},"2026-05-14",{"date":95,"type":38},"2020-07-01",{"date":97,"type":22},"2031-12-31",{"name":44,"class":45},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":46},"100634163","assessing-the-efficacy-and-safety-of-ctdna-driven-selection-for-anti-egfr-retreatment-in-a-real-world-metastatic-colorectal-cancer-patients-cohort-the-realchallenge-study-100634163","NCT07536113","Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)","Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort","RealCHALLENGE","Inclusion criteria\n\n1. Patients diagnosed with MSS RAS and BRAF wild-type (on solid tissue) mCRC and screened by ctDNA within the MEN1611-02 clinical trial;\n2. Informed consent signature from alive patient;\n3. Availability of clinical data detailing the outcome to the first treatment received by patients following the blood draw for ctDNA analysis performed as per screening procedures within the MEN1611-02 clinical trial;\n4. Signed informed consent for molecular screening within the MEN1611-02 clinical trial.\n5. Age ≥ 18.\n\nExclusion criteria\n\n1. No data available detailing the outcome to the first treatment received by patients following the blood draw for ctDNA analysis performed as per screening procedures within the MEN1611-02 clinical trial.\n2. Patients enrolled and treated within the MEN1611-02 clinical trial.",{"count":108,"type":22},250,"This is an observational, retrospective, international and multicenter study funded by Fondazione Oncologia Niguarda ETS to assess the efficacy of anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC patients screened for RAS\u002FBRAF\u002FPIK3CA ctDNA status on liquid biopsy within the MEN1611-02 C-PRECISE-01 trial. The study will collect molecular, clinical and outcome data of patients already available at participating centers.",[111],"Metastatic Colorectal Cancer (CRC)",[113,114,115,116],"liquid biopsy","mCRC","rechallenge therapies","Anti-EGFR","2026-04-15",{"date":119,"type":38},"2026-04-17",{"date":121,"type":38},"2024-03-01",{"date":123,"type":22},"2026-09-01",{"name":44,"class":45},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100604723","the-microscope-project-100604723","NCT07153224","The MICROSCOPE Project","Mentorship, Intraoperative Consultation, and Coaching for Resilience and Outcomes in Early-career Surgeons Through Collaborative Peer Environment (MICROSCOPE): a Prospective International Time-bound Project","MICROSCOPE","Inclusion Criteria:\n\n* Adult patients (≥18 years) treated for abdominal general surgical conditions in the emergency or elective setting or for thoraco-abdominal traumatic diseases. The list of surgical procedures is reported in the Supplementary Material 1\n* Surgeries performed in elective, trauma, or emergency general surgery care\n\nExclusion Criteria:\n\n* Patients operated by surgeons who completed general surgery residency more than 10 years before the study start date\n* Pediatric patients \\\u003C 18 years of age\n* Patients or surgeons not willing to give their consent to participate",{"count":134,"type":22},340,"This multicenter observational prospective study aims to explore the impact of peri-operative support measures (mentorship or coaching or intraoperative consultation) on the mental well-being of early career surgeons. Furthermore sub-analyses will be conducted to explore the impact that surgeons mental wellbeing related to different support measures could have on patients' outcomes",[137,138,139,140,141,142],"Early Career Surgeons","Mental Wellbeing","Patients Outcomes","Mentorship","Surgical Coaching","Intra-operative Consultation",{"date":119,"type":38},{"date":145,"type":22},"2026-06-01",{"date":147,"type":22},"2027-12-31",{"name":44,"class":45},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":161,"conditions":162,"keywords":167,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},"100528279","phase-3-cmp-mythic-trial-and-registry---cardiomyopathy-with-myocarditis-therapy-with-colchicine-100528279","NCT06158698","CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine","Single-blinded Randomized Investigator-initiated Controlled Trial to Assess the Efficacy of Colchicine to Treat Patients With Cardiomyopathy With Myocarditis (Chronic Inflammatory Cardiomyopathy)","CMP-MYTHiC","Inclusion Criteria Trial and Registry:\n\n* Males and females with Infl-CMP associated with VA (including high PVC burden), reduced LVEF, or significantly increased levels of natriuretic peptides.\n* Patients of 18 years or older\n* Evidence of myocardial inflammation on CMRI (using 2018 Lake Louis criteria) or FDG-PET performed in the 3 months before randomization to be included in the trial OR in the last 12 months before for the registry.\n* Presence of any of the following characteristics and if symptoms have been present for more than 1 month:\n* Mono-morphic or polymorphic PVC burden of ≥3000 in 24 hours, or NSVTs (defined as \\>3 more consecutive beat lasting \\\u003C30 seconds) or evidence of sustained ventricular tachycardias (SVT).\n* Reduced LVEF on echocardiogram (\\\u003C50%) or on CMRI (\\\u003C60%)-. Increased N-terminal pro-B-type natriuretic peptide (NT- proBNP) concentration of 1000 pg\u002FmL or more, or a B-type natriuretic peptide (BNP) concentration of 200 pg\u002FmL or more\n* Persistence of increased high-sensitivity troponin levels above the upper reference limit (URL) after at least 2 months from the first assessment and at least a mono-morphic or polymorphic PVC burden of ≥1000 in 24 hours.\n\nExclusion Criteria Registry:\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n\nExclusion Criteria Trial :\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n* Women with childbearing potential (this exclusion criterion is due to insufficient human information regarding the embryofoetal risk with colchicine)\n* Current symptomatic atrial arrhythmias (including persistent atrial fibrillation) associated with LV dysfunction,\n* Advance heart failure (NYHA III or need for inotropes including levosimendan), or recurrent VA despite previous catheter ablation,\n* Known systemic autoimmune disorder or other conditions at the time of randomization where immunosuppression is assumed useful (i.e. cardiac sarcoidosis),\n* Patients already on chronic immunosuppressive therapies (including colchicine) or in whom immunosuppressive therapy is deemed necessary\n* Contraindication to colchicine, including allergies to this medication and its excipients (i.e., lactose and sucrose),\n* Impaired renal function (eGFR\\\u003C30 ml\u002Fmin\u002F1.73m2),\n* Known history of hepatic cirrhosis or transaminase levels at baseline \\> x3-fold the URL\n* Patients with peripheral eosinophilia (eosinophil count \\>10% of the leukocytes) or known hypereosinophilic syndrome at the time of randomization.\n* Severe gastrointestinal insufficiency (for instance, malabsorption syndrome, severe chronic diarrhea)\n* Women during breastfeeding",{"count":158,"type":22},80,[160],"PHASE3","Two-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this population.",[163,164,165,28,166],"Cardiomyopathies","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Arrythmia",[168,169,170,171,172,173,174],"treatment","trial","colchicine","registry","inflammation","outcome","genetic testing",{"date":176,"type":38},"2026-04-20",{"date":178,"type":38},"2023-11-14",{"date":180,"type":22},"2028-05-02",{"name":44,"class":45},10,{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":191,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":46},"100611075","non-invasive-diagnosis-and-monitoring-of-cardiac-masses-by-liquid-biopsy-100611075","NCT07235865","Non-Invasive Diagnosis and Monitoring of Cardiac Masses by Liquid Biopsy","Non-Invasive Diagnosis and Monitoring of Cardiac Masses by Liquid Biopsy: The CarMA Study","CarMA","Inclusion Criteria\n\n1. Age ≥12 years old\n2. Suspected or confirmed diagnosis of a cardiac mass of any nature as assessed by standard clinical, radiological and\u002For pathological procedures.\n\nExclusion Criteria\n\n1\\. Inability of the pa ent to fully understand and sign the informed consent.","12 Years",{"count":193,"type":22},26,"This is a nonprofit, observational, prospective and retrospective,multicenter study in a population of young and adult patients ≥12 years with a diagnosis of a cardiac mass. The study will include both patients with masses of unknown pathological diagnosis and patients with a known histology of benign or malignant tumors. We predict a case-control allocation ratio of 1:1 between cardiac malignant tumors and benign lesions. Peripheral blood will be collected at participating centers during routine venipuncture,processed and then shipped for liquid biopsy ctDNA NGS analyses. If available, in malignant cases, matched tumor tissue samples collected as per clinical practice solid biopsies or surgery will be used for analyses. Longitudinal tracking through serial blood draws could be performed in selected cases of patients with cardiac malignancies who receive cancer treatment",[196],"Cardiac Masses",[198],"Early-Onset Colorectal Cancer","2026-04-13",{"date":117,"type":38},{"date":202,"type":38},"2024-07-25",{"date":204,"type":22},"2026-12-25",{"name":44,"class":45},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":46},"100610627","in-vivo-antibiotics-removal-during-hemoadsorption-cartridges-and-continuous-renal-replacement-therapy-in-the-intensive-care-unit-100610627","NCT07230041","In Vivo Antibiotics Removal During Hemoadsorption Cartridges and Continuous Renal Replacement Therapy in the Intensive Care Unit","In Vivo Antibiotics Removal During Treatment With Hemoadsorption Cartridges and Continuous Renal Replacement Therapy in the Intensive Care Unit","ICARO","Inclusion Criteria:\n\n* stage 3 KDIGO consensus criteria, indication to CRRT\n* use of at least one of the following antibiotics meropenem, linezolid and daptomycin\n* \\\u003C 18 yo\n\nExclusion Criteria:\n\n* \\\u003C 18 yo",{"count":215,"type":22},20,"The purpose of this study is to measure the change in plasma concentrations of antibiotics used during passage through the CRRT filter and hemadsorption cartridge in patients with septic shock and renal failure requiring CRRT.\n\nAll patients aged \\> 18 years, admitted to the ICU, diagnosed with septic shock and renal failure requiring CRRT, receiving antibiotic therapy with at least one of the following drugs: meropenem, linezolid, and daptomycin, who provided informed consent, are included in the study.\n\nPatients not admitted to the ICU, patients with renal failure not requiring CRRT, patients aged \\\u003C 18 years, or those who did not provide informed consent are excluded. The enrollment period will last 12 months and will run from September 2024 to September 2025. The expected number of patients enrolled is twenty. To proceed with the study, after starting antibiotic therapy, a 4 ml dose of blood will be drawn (Vacuette tube ref. 454092) before the cartridge, immediately after, and after the dialysis filter. This measurement will be repeated after 4, 8, and 12 hours, which represents the maximum usage time of the cartridge.\n\nAfter 12 hours, the cartridge becomes saturated and loses its adsorption capacity.\n\nThe CRRT filter, however, remains in place for at least 72 hours before being replaced. Treatment is maintained until clinically necessary.\n\nFor patients in intensive care, several blood samples are required throughout the day, both with a blood sample sent to the biochemistry laboratory every 6-8 hours to check clinical conditions, and with an arterial blood sample (blood gas) to check respiratory and metabolic status in patients on mechanical ventilation. Furthermore, in patients undergoing CRRT, electrolyte balance must be monitored every 4 hours. Therefore, the blood sample for the study inevitably coincides with one of the routine blood samples.\n\nThe test tube, labeled with a unique code, will be sent to the central laboratory, which will centrifuge the blood and extract the plasma. This aliquot will then be stored at -80°C in a dedicated space and sent to the designated laboratory upon analysis.\n\nDetermination of the plasma dosage of the antibiotic in use is commonly performed on patients admitted to the Intensive Care Unit, where clinically necessary. Participation in the study does not change current clinical practices.",[218],"Septic Shock",[220,221,222,223,224,225],"antibiotic","target drug monitoring","meropenem","linezolid","daptomycin","in vivo",{"date":117,"type":38},{"date":228,"type":38},"2025-01-15",{"date":230,"type":22},"2026-08-15",{"name":44,"class":45},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":46},"100540192","vascular-senescence-and-atherosclerotic-plaque-vulnerability-100540192","NCT06313645","Vascular Senescence and Atherosclerotic Plaque Vulnerability","Cellular and Molecular Mechanisms of Vascular Senescence and atherosclerotIC Plaque Vulnerability: the TelOmere-mitochondRIa Cross-tAlk Study","VICTORIA","Inclusion Criteria:\n\n* Patients with acute coronary syndromes (unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI))\n* stable angina\n* non-angiographically significant coronary diseases recovered for elective diagnostic or interventional procedures\n\nExclusion Criteria:\n\n* cardiac shock\n* congestive heart failure\n* end stage renal diseases\n* coronary artery bypass graft\n* active cancer","75 Years",{"count":242,"type":22},300,"Chronological aging significantly contributes to structural and functional alterations in the vasculature, making it a major risk factor for atherosclerotic disease and its acute thrombotic events. DNA damage, including telomeric, non-telomeric, and mitochondrial damage, is recognized as a key initiator of vascular aging and atherogenesis. There is abundant evidence indicating the presence of oxidative DNA lesions, telomere erosion, and mitochondrial DNA damage in both experimental and human plaques, as well as in the peripheral cells of atherosclerotic patients.\n\nIt is increasingly evident that genomic instability activates signaling pathways that lead to a multitude of pathophysiological cellular and molecular changes. These changes promote inflammation, apoptosis, autophagy, and ultimately, cellular senescence, accompanied by the \"senescence-associated secretory phenotype\" (SASP). However, the precise mechanisms linking the DNA damage response (DDR) to senescence, SASP in vascular cells, and the pathogenesis of atherosclerosis and vulnerable atheroma are yet to be fully understood. Additional research is needed to delineate the underlying mechanisms through which mitochondrial dysfunction influences telomere length and vice versa, and how their interaction contributes to the vascular aging process. Progress in this area has the potential to uncover therapeutic targets and novel, more precise diagnostic, and prognostic indicators.\n\nThe objectives of the VICTORIA study are to examine the levels of aging-related non-coding RNA deregulation (specifically lncRNA TERRA and mitomiR) and peripheral markers of cell aging (including telomere length and mitochondrial DNA content) across the various spectra of angina pectoris (stable angina, unstable angina, NSTEMI, and STEMI). Additionally, the study aims to determine whether these markers are correlated with vulnerable plaque characteristics and major adverse cardiovascular events.",[245],"Coronary Artery Disease",[247,248,249,250],"Vascular senescence","Genetic instability","Mitochondrial deregulation","Coronary syndrome",{"date":252,"type":38},"2026-04-16",{"date":254,"type":38},"2023-07-01",{"date":147,"type":22},{"name":44,"class":45},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":265,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":46},"100533025","blunt-adrenal-gland-injury-bad-guy-project-100533025","NCT06220448","Blunt ADrenal Gland injUrY (BAD GUY) Project","Exploring the Epidemiology and Burden of Blunt Adrenal Gland Injury in the Context of Major Trauma","BADGUY","Inclusion criteria:\n\n* Age \\> 16 years old\n* All patients with blunt thoraco-abdominal trauma\n\nExclusion criteria:\n\n* TBI with AIS \\> 3\n* Isolated TBI and Spinal cord injury\n* Patients died in emergency department","16 Years","99 Years",{"count":268,"type":22},5000,"Type: retrospective observational multicenter trial. Population of interest: adult patients suffering from thoraco-abdominal trauma undergoing both non-operative and operative management.\n\nHypothesis: Adrenal gland injury is a rare finding after blunt thoracoabdominal trauma. Short-term outcomes of blunt adrenal gland injury (BAGI) described in literature are contradictory. Reports on the outcomes related to this injury are variable and consider heterogeneous populations of trauma patients Aim: This study aims to explore the burden related to BAGI in an homogeneous population of patients sustaining blunt thoraco-abdominal trauma treated in different institution",[271,272],"Trauma","Adrenal Gland Injury",[271,274,275],"blunt adrenal gland trauma","major trauma",{"date":252,"type":38},{"date":278,"type":38},"2024-01-01",{"date":280,"type":22},"2027-09-30",{"name":44,"class":45},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":290,"targetDuration":292,"studyType":84,"phases":4,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":46},"100527146","ultrasound-assisted-catheter-directed-thrombolysis-for-acute-intermediate-high-risk-pulmonary-embolism-100527146","NCT06143969","Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism","Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism (USAT IH-PE): Impact on Short- and Long-term Outcome, a Multi-center Experience. An Observational Retrospective and Prospective Multi-center Study","USAT IH-PE","Inclusion Criteria\n\n* Patients admitted with acute intermediate-high risk PE, defined according to ESC guidelines\n* Symptoms onset within previous 14 days associated or not with deep venous thrombosis\n* Confirmation of the PE by contrast-enhanced computed tomography of the chest with embolus located in at least one main or proximal lower lobe pulmonary artery\n* Echocardiographic parameters of RV disfunction\n* Patients with high-risk PE or hemodynamic deterioration on anticoagulation, who have absolute contraindications (high bleeding risk) to systemic thrombolysis and symptoms onset during the last 14 days. Patients with surgery-related embolic complications are also included (within 48 hours).\n\nExclusion Criteria\n\n* Age \\\u003C 18 years old\n* Patients unable to give informed consent\n* Pregnancy\n* Patients received fibrinolytic drugs in the preceding 4 days\n* Bleeding diathesis\n* Known bleeding disorder\n* Low platelet count (\\\u003C 100.000\u002FuL\n* Gastrointestinal bleeding in the preceding 3 month\n* Any ongoing known presence of malignant neoplasia months\n* Advanced chronic kidney disease (defined as 11.000\u002FuL)\n* Gastrointestinal bleeding in the preceding 3 month\n* Any ongoing known presence of malignant neoplasia at admission with survival rate \\\u003C 6\n* Advanced chronic kidney disease (defined as eGFR \\\u003C 30 ml\u002Fmin or on dialysis)",{"count":291,"type":22},180,"6 Months","The purpose of this retrospective and prospective multicenter study is to evaluate the incidence of pulmonary hypertension (PH) within 6 months from ultrasound-assisted, Catheter-directed Thrombolysis for acute intermediate- high-risk Pulmonary Embolism",[295],"Pulmonary Embolism",[297,298,299,300],"pulmonary embolism","intermediate high-risk","Ultrasound-assisted","Catheter-directed Thrombolysis",{"date":252,"type":38},{"date":303,"type":38},"2022-11-28",{"date":305,"type":22},"2027-03-31",{"name":44,"class":45},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":315,"targetDuration":317,"studyType":84,"phases":4,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":328},"100516163","ischemic-and-bleeding-risk-assessment-after-tavr-100516163","NCT06000943","Ischemic And Bleeding Risk Assessment After TAVR","Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)","FOCUS ONE","Inclusion criteria\n\n* All patients with severe aortic stenosis undergoing TAVR.\n* Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR.\n\nExclusion Criteria\n\n* Patients who died during the index procedure\n* Patients in triple antithrombotic therapy at discharge\n* Patients with a known prognosis less than 1 year at the time of TAVR",{"count":316,"type":22},2500,"3 Years","Transcatheter aortic valve replacement (TAVR) represents an effective treatment to improve symptoms and prognosis in patients with symptomatic severe aortic stenosis (AS) (1-2).\n\nGiving an established uniform approach towards anticoagulation and antithrombotic therapy after TAVR in the post POPULAR-TAVI era, recent data coming from the analysis of different trials, highlight the relevance of the patient's background on the occurrence of ischemic and bleeding events.\n\nDespite this a targeted antithrombotic strategy remains unexplored and all patients undergoing TAVR without other indication to DAPT or OAC, were currently treated according with the concept of \"less is more\" (only SAPT or only OAC) regardless the risk level (5-6).\n\nThe keys points of the project will be 1) the assessment of ischemic and bleeding risk after TAVR stratified according with antithrombotic therapy and surgical risk; 2) the evaluation of the impact of prostheses type and the complete blood count variables (hemoglobine and platelets) on the daily average ischemic and bleeding risk and 3) the evaluation of the dynamic therapeutic changes after TAVR during the follow up.",[320,321],"Aortic Valve Stenosis","Transcatheter Aortic Valve Replacement",{"date":252,"type":38},{"date":324,"type":38},"2023-08-01",{"date":326,"type":22},"2026-12-15",{"name":44,"class":45},12,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":46},"100499171","coronary-re-engagement-after-random-navitor-alignment-comfort-study-100499171","NCT05779787","COronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY)","COronary Re-EngageMent aFter RandOm NavitoR Alignment (COMFORT STUDY)","COMFORT","Patients to be included in this registry should have all the following criteria:\n\n1\\. Severe, symptomatic aortic stenosis with an indication to TAVI\n\nExclusion criteria and definition\n\nPatients excluded in this registry should have all the following criteria:\n\n1. Valve in Valve procedure\n2. Hemodynamical instability\n3. TAVR performed from other access (not femoral)\n4. No-CT Planned TAVR\n5. TAVR performed with Chimney Technique",{"count":338,"type":22},100,"Whereas PCI before TAVR was previously recommended despite its uncertain prognostic role, recent data underline the possibility of a postponed coronary intervention using a commissural alignment technique. This approach allows easy coronary re-engagement through the valve stent frame with a trade off paid of procedure complexity.\n\nConsidering the prevalence of coronary artery disease (CAD) and the increasing percentage of younger patients treated with TAVI, investigate whether a simpler procedure with random implantation of Navitor valve is not inferior in terms of coronary re-access, is required The key point of the project will be the evaluation of the feasibility of coronary re-engagement after a Navitor valve randomly implanted.",[320,321],{"date":252,"type":38},{"date":343,"type":38},"2023-02-15",{"date":345,"type":22},"2027-05-15",{"name":44,"class":45},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":371,"locationsCount":46},"100487501","the-psean-study---study-protocol-100487501","NCT05627908","The PseAn Study - Study Protocol","Detection of Post-traumatic Abdominal Pseudoaneurysms by CEUS and CT: A Prospective Comparative Global Study","PseAn","Inclusion Criteria:\n\n* adult patients (18 years old and above) with proven blunt or penetrating splenic and\u002For liver and\u002For renal trauma as shown by a CT scan and classified according to the American Injury Scale American Association for Surgery (AAST) Organ Injury Scale (OIS) will be included\n\nExclusion Criteria:\n\n* minor to 18 years old",{"count":356,"type":22},385,"The researchers aim to study the role of contrast ultrasound in detecting post-traumatic splenic, hepatic, and renal PAs compared with the gold standard of CT with intravenous contrast at different follow-up time points, and whether it can replace CT scan in the follow-up of solid organ injuries",[359,360],"Abdominal Trauma","Follow-up in Abdominal Trauma",[362,363,364,365,366],"trauma","CT scan","CEUS","follow up","abdominal pseudoaneurism",{"date":252,"type":38},{"date":369,"type":38},"2022-10-01",{"date":147,"type":22},{"name":44,"class":45},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":388,"leadSponsor":390,"locationsCount":46},"100447358","evaluation-of-serratus-plane-block-on-the-respiratory-pattern-in-patients-with-multiple-rib-fractures-100447358","NCT05105399","Evaluation of Serratus Plane Block on the Respiratory Pattern in Patients With Multiple Rib Fractures","Evaluation of Serratus Plane Block on the Respiratory Pattern in Patients With Multiple Rib Fractures: a Perspective Randomized Controlled Study","Inclusion Criteria:\n\n1. Chest trauma with at least 2 monolateral rib fractures (monofocal or multifocal) with no flail chest\n2. Age\\>18 years\n3. Hospital admission\n4. Ability to provide written informed consensus\n5. Awake patient, spontaneous ventilation",{"count":380,"type":22},72,[25],"In patients admitted following a trauma, the incidence of multiple rib fractures is reported to be 9,7%, and this can be even higher in high energy trauma like motor vehicle accidents (1). Pain deriving from rib fractures cause the patient to breath shallow in order to limit discomfort and this bring about negative consequences: shallow breathing and inability to clear secretions may cause pulmonary atelectasis eventually evolving to pneumonia. Given the aforementioned concerns, it is easy to understand why, in a context like this, control of chest pain become crucial. The best way to achieve adequate pain control have not yet been established: the aim of this study is to investigate on this clinical dilemma. In this study, 72 people with at least two monolateral rib fractures are going to be randomized into three groups: 1) standard treatment alone (intravenous analgesia: acetaminophen + morphine PCA); 2) continuous serratus plane block + standard treatment; 3) single-shot serratus plane block + standard treatment. The variables that are going to be recorded are the following: pain through the NRS scale, FEV1 and FVC through spirometry and finally an arterious gas analysis. Recording are going to be repeated at 72h after admission. The primary endpoint is to evaluate if the continuous serratus plane block is able to improve the FEV1\u002FFVC compared to single shot or standard treatment alone. Secondary endpoints will be: the effect of continuous block on 1) resting and incident pain; 2) opioid consumption; 3) blood gas analysis parameters; 4) pulmonary complications at 1 month; 5) length of stay",[384,385],"Rib Fractures","Spirometry",{"date":252,"type":38},{"date":145,"type":22},{"date":389,"type":22},"2027-05-01",{"name":44,"class":45},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":402,"conditions":403,"keywords":406,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":417,"locationsCount":46},"100445039","re-assessment-of-appendicitis-evaluation-during-laparoscopic-appendectomy-peritoneal-irrigation-during-laparoscopic-appendectomy-does-the-grade-of-contamination-matter-100445039","NCT05075252","Re-assessment of Appendicitis Evaluation During Laparoscopic Appendectomy, Peritoneal Irrigation During Laparoscopic Appendectomy Does the Grade of Contamination Matter?","REsiDENT1 (Re-assessment of Appendicitis Evaluation During Laparoscopic Appendectomy: Do we End a Non-standardized Treatment Approach and Habit?): Peritoneal Irrigation During Laparoscopic Appendectomy-Does the Grade of Contamination Matter? A Prospective Multicenter Resident-based Evaluation of a New Classification System","RESIDENT1","Inclusion Criteria:\n\n* Patients between 18 and 69 years old\n* Surgical laparoscopic approach for AA\n* Intra-operative and histological diagnosis of AA\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years old or \\> 69 years old\n* Previous appendectomy\n* Previous appendicitis treated conservatively\n* Open approach for surgery or intra-operative conversion\n* Co-existence of other intra-abdominal infections (IAI)\n* Patients with immunodeficiency\n* Patients treated with steroid, immunosuppressant, or CHT within previous 6 months","69 Years",{"count":401,"type":22},1067,"Type: prospective observational multicenter trial. Population of interest: adult patients undergoing laparoscopic appendectomy for acute appendicitis.\n\nHypothesis : laparoscopic lavage during laparoscopic appendectomy is a practice that should be used in selected patients according to the intraperitoneal grade of contamination and grade of appendicitis. Nonregulated use of laparoscopic lavage cannot be considered superior to suction only considering recent evidence. Few RCT available addressing this issue are available, but any with a high methodological quality.\n\nAim: The aim of this study is to investigate the impact of laparoscopic lavage during laparoscopic appendectomy on the postoperative incidence of intrabdominal abscesses, stratifying patients in different clusters according to a defined classification considering the intraperitoneal contamination and grade of appendicitis.",[404,405],"Appendicitis","Appendectomy",[407,408,409,410,411,412],"laparoscopy","appendicitis","appendectomy","lavage","suction","abscess",{"date":252,"type":38},{"date":415,"type":38},"2019-10-01",{"date":280,"type":22},{"name":44,"class":45},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":428,"conditions":429,"keywords":431,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":46},"100434921","icg-indocyanine-green-imaging-fluorescence-technology-in-surgical-treatment-of-advanced-gastric-cancer-100434921","NCT04943484","ICG (Indocyanine Green) Imaging Fluorescence Technology in Surgical Treatment of Advanced Gastric Cancer","[The iGreenGO Study]. Investigation About the Clinical Value of Indocyanine Green Imaging Fluorescence (NIR\u002FICG) Technology as a Modifier of Surgeon's Conduct During Curative Treatment of Advanced Gastric Cancer. Study Protocol for a Western, Observational, Prospective, Multicentric Study","iGreenGO","Inclusion criteria\n\n* Age ≥ 18 years old\n* Preoperative histologically proven adenocarcinoma of the upper, middle or lower part of the stomach.\n* Advanced disease (Staged cT2-T4a, N0-3;M0 according to 8th edition of the AJCC TNM Staging System) at diagnosis, in which resection can be safely achieved by distal or total gastrectomy with D2 lymphadenectomy via a minimally invasive (laparoscopic or robotic) approach, either as first treatment or after neoadjuvant treatment\n* No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in the preoperative and intraoperative examinations\n* Written informed consent\n\nExclusion criteria\n\n* Women during pregnancy or breast-feeding\n* History of previous upper abdominal surgery (laparoscopic cholecystectomy will be allowed)\n* History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection\n* History of allergy to iodine agents\n* Cancer located at the esophago-gastric junction (Siewert I, II, III tumors 29)\n* Patients candidates to transthoracic esophagectomy, transhiatal extended gastrectomy or proximal gastrectomy\n* History of previous neoadjuvant chemotherapy (except perioperative chemotherapy for gastric cancer) or radiotherapy",{"count":427,"type":22},360,"The iGreenGO Study aims to investigate whether the intraoperative application of NIR\u002FICG technology is associated with a change in the surgical conduct (CSC) during curative-intent gastrectomy with D2 lymphadenectomy in a cohort of Western patients affected by AGC. The preoperative clinical variables potentially associated with CSC will be also investigated",[430],"Gastric Cancer",[432,433,434,435,436,437,438],"advanced","gastric cancer","indocyanine green","ICG","surgery","D2 lymphadenectomy","surgical conduct",{"date":252,"type":38},{"date":441,"type":38},"2022-01-01",{"date":443,"type":22},"2026-11-30",{"name":44,"class":45},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":461,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100421147","reflux-disease-after-gastric-bypass-versus-sleeve-gastrectomy-in-morbid-obese-patients-an-italian-study-100421147","NCT04763993","Reflux Disease After Gastric Bypass Versus Sleeve Gastrectomy in Morbid Obese Patients: an Italian Study","Reflux Disease After Gastric Bypass Versus Sleeve Gastrectomy in Morbid Obese Patients: an Italian Monocentric Randomized Clinical Study (ReBvSS)","ReBvSS","Inclusion Criteria:\n\n* Acceptance of randomization to surgery;\n* Participant is willing and able to give informed consent for participation in the trial;\n* Written informed consent;\n* Compliance to follow-up;\n* Male and female;\n* ≥18 and ≤70 years old;\n* BMI ≥ 35 with obesity-related comorbidities;\n* BMI ≥ 40 with or without obesity-related comorbidities;\n* GERDQ score ≥ 3 points;\n* Use of proton pump inhibitor;\n* Mild and Moderate GERD (DMS ≥14.72 ≤100)\n* Incompetence of the Esophagogastric junction\n* Los Angeles grade A, B, C, D esophagitis.\n\nExclusion criteria\n\n* Medical or psychiatric conditions that compromises the patient's ability to give informed consent or comply with the study protocol;\n* Barrett's esophagus (BE);\n* Spastic motor disorders and esophageal hypomotility;\n* Peptic strictures;\n* Absence of GERD (DMS\\\u003C14.72);\n* Severe GERD (DMS\\>100);\n* Hiatal hernia \\> 5 cm;\n* Previous bariatric surgery or major general surgery;\n* Type 2 diabetes (T2D) for more than \\> 5 years;\n* Necessity to explore stomach, the duodenum or the biliary tract;\n* Refuse of randomization;\n* Personal reasons.","70 Years",{"count":455,"type":22},128,[25],"The study aims to clarify if GERD, defined by results of 24 hours potential of hydrogen (pH) monitoring and abnormal DeMeester Score (DMS), in obese patients could worsen after Sleeve Gastrectomy (SG) more than after RYGBP. To demonstrate this hypothesis, the investigators will study the obese population suspected for GERD with 24 hours monitoring and High-Resolution Esophageal Manometry (HRM). DMS is calculated pre-operatively and, once GERD is confirmed, the patients are enrolled for randomization to SG or RYGBP. The suspicion of GERD is investigated with the GERDQ score and EGDS, that all obese patients have pre-operatory.",[459,460],"Gastroesophageal Reflux Disease","Obesity",[459,460,462,463,464,465],"Sleeve gastrectomy","Gastric bypass","DeMeester score","pH-monitoring",{"date":252,"type":38},{"date":468,"type":22},"2026-05-01",{"date":470,"type":22},"2030-05-01",{"name":44,"class":45},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":46},"100387333","cardiogenic-shock-integrated-phenotyping-for-event-reduction-100387333","NCT04323371","Cardiogenic Shock Integrated PHenotyping for Event Reduction","CIPHER","Inclusion Criteria:\n\n* Age ≥ 18 and \\\u003C 75, men and women;\n* 1\\) Systolic blood pressure (SBP) \\\u003C 90mmHg or mean arterial pressure (MAP) \\\u003C 60 mmHg, after an appropriate fluid challenge if there is no sign of overt fluid overload; OR 2) need of vasoactive agents to maintain SBP \\> 90 mmHg or MAP \\> 60 mmHg.\n* Reduced ejection fraction (left ventricle systolic function ≤35%).\n* Moreover, eligible patients have to fit at least ONE of the following criteria\u002Fitems of overt hypoperfusion: altered state of consciousness; sweaty and cold skin; mixed venous oxygen saturation \\\u003C 60%; arterial lactates \\> 2 mmol\u002FL; oliguria \\\u003C 0.5 ml\u002FKg\u002Fh for at least 6 hours.\n* Eligible patients shouldn't have contraindications to heart replacement therapy (HRT).\n\nExclusion Criteria:\n\nThe participant will not be enrolled if ANY of the following criteria will be detected:\n\n* Cardiogenic shock symptoms beyond 6 hours.\n* Septic shock with evident septic focus.\n* Cardiogenic shock due to acute myocardial infarction.\n* Cardiogenic shock due to acute myocarditis.\n* Cardiogenic shock due to pulmonary thromboembolism.\n* Reiterating major arrhythmias: VT or VF or AF, with ventricular rate \\> 160 bpm.\n* Severe aortic valve disease.\n* Obstructive hypertrophic cardiomyopathy or constrictive pericarditis or severe heart failure due to congenital heart disease\n* Severe peripheral vascular disease that contraindicates mechanical support insertion.\n* Cardiogenic shock secondary to either cardiac or non-cardiac surgery.\n* Comorbidities with ominous prognosis (life expectancy \\\u003C 1 year).\n* Estimated glomerular filtration rate severely impaired before enrolment (eGFR\\\u003C30 ml\u002Fmin\u002F1.73 m2) or severe chronic obstructive pulmonary disease (COPD) or liver cirrhosis.\n* Pregnant, lactating or subjects planning pregnancy during the course of the trial.\n\nAny other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial","74 Years",{"count":193,"type":22},"The purpose of this study is to better understand the time course of different biological mechanisms involved in acute decompensated heart failure complicated by cardiogenic shock throughout the evaluation of changes and the relationship among markers of inflammation (IL-6) and markers of increased endothelial permeability (Ang-2) or endothelial glycocalyx perturbation (Syndecan-1 and HS) and throughout a targeted metabolomic approach.",[28],[484,89,485,486,487],"heart failure","endothelial glycocalyx","Angiopoietin (Ang)-2","Metabolomics",{"date":252,"type":38},{"date":490,"type":38},"2020-06-30",{"date":492,"type":22},"2028-03-01",{"name":44,"class":45},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":46},"100343965","non-invasive-ventilation-versus-high-flow-oxygen-100343965","NCT03758508","Non-invasive Ventilation Versus High Flow Oxygen","Non-invasive Ventilation Versus High Flow Oxygen Through Nasal Cannula in Pneumonia Associated Acute Hypoxemic Respiratory Failure","HFO","Inclusion Criteria:\n\n* Diagnosis of pneumonia based on at least two clinical\u002Flaboratory criteria and 1 radiologic criterion among the following:\n\n  * Clinical criteria: fever, cough, purulent sputum, pulmonary examination positive for signs consistent with pneumonia\n  * Laboratory criteria: leukocytosis (White blood cells \\>10000\u002FmcL) or leukopenia (White blood cells \\\u003C 4000\u002FmcL), rise of the inflammatory markers\n  * Radiologic criteria: consolidations at Chest X-ray or CT scan\n* Hypoxemic respiratory failure, based on all the following criteria\n\n  * PaO2\u002FFiO2 \\\u003C 300 after at least 15 minutes conventional oxygen therapy with a FiO2 ≥ 50%\n  * Respiratory Rate (RR) ≥ 25\u002Fmin or need for use of accessory muscles\n* Informed consent to study participation\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Hypercapnic respiratory failure (pCO2 \\> 60 mmHg at presentation) such as in Chronic Obstructive Pulmonary Disease\n* Presence of another cause of hypoxemic respiratory failure - e.g. pulmonary embolism, acute respiratory distress syndrome (ARDS), pulmonary oedema\n* Hemodynamic instability with necessity for use of inotropes and\u002For vasopressors\n* Indication for endotracheal intubation (ETI): Glasgow Coma Scale (GCS) \\\u003C8, agitation, device intolerance, respiratory arrest\n* Immunosuppression (chronic immunosuppressive therapy, clinical history positive for any immunodeficiency - congenital or acquired)\n* Do Not Resuscitate (DNR) and Do Not Intubate (DNI) indication\n* Tracheostomy\n* Nocturnal CPAP ventilation therapy\n* Any other condition which the clinician would considered an adjunctive risk for taking part in the study or that would not permit the participant to complete it",{"count":455,"type":22},[25],"The purpose of the study is to compare the efficacy of alternating Non Invasive Ventilation NIV and High Flow Oxygen HFO compared to High Flow Oxygen HFO alone on gas exchanges and prognosis in pneumonia-associated acute hypoxemic respiratory failure",[506],"Pneumonia-associated Acute Hypoxemic Respiratory Failure",[508,509,510,511],"Noninvasive ventilation","High flow oxygen nasal cannula","Pneumonia","Acute hypoxemic respiratory failure",{"date":252,"type":38},{"date":514,"type":38},"2017-11-01",{"date":516,"type":22},"2027-12-01",{"name":44,"class":45},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":525,"targetDuration":526,"studyType":84,"phases":4,"briefSummary":527,"conditions":528,"keywords":530,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":537,"leadSponsor":539,"locationsCount":46},"100331933","embotrap--ii-revascularization-device-neuravi-in-acute-ischemic-stroke-100331933","NCT03601702","EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke","Multicentric Observational Prospective Study on the Use of the EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke","Inclusion Criteria\n\n* Signed Informed Consent Form\n* Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1\n* ASPECTS ≥ 6\n* Mismatch or good collaterals showed at MR or multiphasic CTA or pCT\n* Groin Puncture performed within 12 hours from symptom onset\n* Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment\n\nExclusion criteria\n\n* Informed consent not given\n* Extracranial or tandem occlusion",{"count":338,"type":22},"3 Months","The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.",[529],"Acute Ischemic Stroke",[531,532,533,534],"acute ischemic stroke","endovascular treatment","stent retriever device","mechanical thrombectomy",{"date":252,"type":38},{"date":441,"type":38},{"date":538,"type":22},"2027-06-15",{"name":44,"class":45},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":18,"minAge":317,"maxAge":547,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":46},"100593746","microbiota-gut-brain-axis-in-resistant-epilepsy-100593746","NCT07010445","MiCrobiota-gut-brain Axis in Resistant Epilepsy","CARE","Inclusion criteria:\n\n* 3-50 years old;\n* diagnosis of epilepsy at onset or DRE;\n* ensured participation of the patient or a caregiver;\n* willingness to sign the informed consent.\n\nExclusion criteria:\n\n* diagnosis of organic gastrointestinal disorders (e.g. chronic inflammatory bowel disease);\n* special diets;\n* use of antibiotics, corticoids or probiotics in the previous month.","50 Years",{"count":549,"type":22},120,[25],"Epilepsy is one of the most common neurological chronic conditions with a serious burden on patients, their caregivers, and society. Drug-resistant epilepsy (DRE) heightens this burden. New approaches are thus a priority. Studies in animal models and humans have shown the link between gut microbiota (GM) and the central nervous system in health, neurological conditions, and neurodevelopmental disorders. DRE has been linked to GM dysbiosis. Preliminary findings in children with DRE showed GM modifications when responding to a ketogenic diet. The mediator role of GM has not yet been studied in DRE patients undergoing surgery\u002Fvagal nerve stimulation.\n\nCARE's central hypothesis is that the GM and its metabolic profile could contribute to clinical outcomes following these different therapeutic procedures. Identifying microbial biomarkers will enable us to deepen the knowledge of the role of gut-brain axis in epilepsy and to tailor the intervention to each patient based on GM modulation.",[553,554,555],"Gut Microbiota","Epilepsy","Drug-Resistant Epilepsy","2026-04-06",{"date":558,"type":38},"2026-04-09",{"date":560,"type":38},"2024-08-16",{"date":562,"type":22},"2027-02",{"name":44,"class":45},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":46},"100626185","decoding-epigenetic-mechanisms-driving-immune-evasion-in-liver-cancer-with-omics-approaches-100626185","NCT07432347","Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches","DELIVER","1. Histological\u002Fradiological (LR-4 o 5)diagnosis of hepatocellular carcinoma (HCC).\n2. Solid tumor fresh tissue availability from HCC biospy or surgical resectionas per standard clinical practice, and\u002ForHCC FFPE archival samples availability.\n3. Capability of understanding and signing an inform consent form.\n4. Known hepatits B and C status, including HBeAg (positive or negative), viral load (HBVDNA e HCV-RNA), HCV genotype, whether sustained virological response (SVR)was obtainedand potential antiviral treatments received (including direct antiretroviral therapy(DAA)and interferon). These parameters will be exploited to stratify patients and analyze the impact of the virological status on microenvironmental immunological features, with particular regards to immunesuppression mechanisms.",{"count":572,"type":22},270,"This is a national, observational, retrospective, cross-sectional, non-profit study focused on patients with HCC. The study aims to characterize the expression and function of novel noncoding regulatory transcripts, including those containing TEsin the microenvironment of liver tumors, with emphasis on their role in T cell dysfunction.",[575],"Hepatocarcinoma","2026-02-24",{"date":578,"type":38},"2026-02-27",{"date":580,"type":38},"2026-01-01",{"date":582,"type":22},"2031-01-31",{"name":44,"class":45},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":46},"100615862","cardiac-assessment-for-thrombus-detection-in-the-heart-using-advanced-imaging-mri-ct-in-esus-with-left-ventricular-disease-100615862","NCT07298122","Cardiac Assessment for Thrombus Detection in the Heart Using Advanced Imaging (MRI, CT) in ESUS With Left Ventricular Disease","CATCH ME","Inclusion Criteria:\n\n* Age between 18 and 85 years Modified Rankin Scale (mRS) score ≤ 4 Diagnosis of acute ischemic stroke (detected by CT or brain MRI) Diagnosis of ESUS according to standard criteria\n* Stroke detected by CT or MRI that is not lacunar. Lacunar is defined as a subcortical infarction (including pons and mesencephalon) in the distribution of the small penetrating cerebral arteries, with a maximum size ≤ 1.5 cm on CT or ≤ 2.0 cm on diffusion-weighted MRI images (\\\u003C 1.5 cm on T2-weighted MRI images). Excluded: multiple small deep infarcts, lateral bulb infarcts, cerebellar infarcts, patients with clinical lacunar stroke syndrome and no visible infarction on imaging.\n* Absence of extracranial or intracranial atherosclerosis causing ≥ 50% stenosis in the artery supplying the ischemic area. Vascular imaging of the extracranial and intracranial vessels is required using angiography, CT angiography (CTA), MR angiography (MRA), or color Doppler ultrasound, at the discretion of the treating physician and local principal investigator.\n* No major cardioembolic source identified, including permanent or paroxysmal atrial fibrillation (AF), sustained atrial flutter, intracardiac thrombus (\\*as specified above, these patients will be recruited in phase 1 of the study only if an isolated ventricular thrombus is found without other major cardiac causes), mechanical heart valve prosthesis, atrial myxoma or other cardiac tumors, moderate or severe mitral stenosis, recent myocardial infarction (\\\u003C 4 weeks), left ventricular ejection fraction (EF) \\\u003C 30%, valve vegetations or infective endocarditis.\n* No other identified cause of stroke (such as arteritis, dissection, migraine, vasospasm, drug abuse, hypercoagulability, etc.)\n\nPresence of LVD defined by at least one of the following criteria:\n\n* Moderately reduced left ventricular (LV) systolic function, defined as EF 30-49%.\n* LV wall motion abnormalities (LVWMAs), defined as hypokinetic, akinetic, or dyskinetic segments of the left ventricular wall not associated with recent or acute myocardial infarction (within 4 weeks).\n* LV aneurysm\n* Enlarged LV with or without spontaneous contrast\n* Non-compacted LV, with deep trabeculations or spongy LV\n* Cardiomyopathies, such as restrictive cardiomyopathy, hypertrophic cardiomyopathy, or cardiac amyloidosis\n\nPatients capable of signing informed consent (IC) or, in the case of unconscious patients without an authorized legal representative, recruited in a \"Deferred\" mode\n\nExclusion Criteria:\n\n* Major cardioembolic sources, as specified in the ESUS criteria Patients with a thrombophilic state secondary to active cancer, defined as \"diagnosis of solid or hematologic malignant tumor within 6 months of stroke, ongoing oncological treatment, or hematologic cancer not in remission.\" Patients with ipsilateral carotid plaques to the ischemic stroke considered at high risk: thrombus on the wall, floating thrombus, ulcerated plaque.\n\nPatients under 60 years of age with a high-risk patent foramen ovale (PFO) and stroke classified as \"probable\" PFO-associated stroke according to the PASCAL classification.\n\nPregnancy or puerperium. Contraindication to MRI and CT with contrast agents",{"count":592,"type":22},125,"The CATCH ME study is a prospective, multicenter, observational, no-profit study aimed at improving embolic risk stratification in patients with embolic stroke of undetermined source (ESUS), particularly in those with left ventricular disease (LVD). LVD is defined by a mildly to moderately reduced ejection fraction (30-49%), left ventricular wall motion abnormalities (hypo\u002Fakinesia), ventricular dilation, cardiomyopathies, and other related conditions. In these patients, the intermittent formation of intracardiac thrombi within the ventricle, often undetectable by standard diagnostic evaluation such as transthoracic echocardiography (TTE) alone, may serve as an unrecognized embolic source. However, in clinical practice, such patients are frequently discharged on antiplatelet therapy alone, without adequate thromboembolic risk stratification, thus leaving them at a high risk of ischemic recurrence. This study aims to assess the additional diagnostic value of advanced cardiac imaging - Cardiac Magnetic Resonance Imaging (CMRI) and\u002For Cardiac Computed Tomography (CCT) - in detecting intracardiac thrombi not identified by TTE in patients with ESUS and LVD.",[595],"Cryptogenic Ischemic Stroke","2025-12-11",{"date":598,"type":38},"2025-12-23",{"date":600,"type":38},"2025-09-15",{"date":602,"type":22},"2028-12-31",{"name":44,"class":45},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":46},"100610963","clinical-trial-addressing-the-best-surgical-approach-for-partial-nephrectomy-with-single-port-robotic-system-in-the-management-of-localized-renal-cell-carcinoma-100610963","NCT07234409","Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma","Standard Flank Approach vs Supine Approach for Robot-assisted Partial Nephrectomy","K3","* Age ≥ 18 years;\n* Presence of a single, unilateral, primary renal mass ≤ 7 cm in diameter (clinical stage cT1) documented CT scan\n* No evidence of systemic disease or lymph node involvement;\n* Candidate for robot-assisted partial nephrectomy using the Da Vinci SP platform;\n* Signed informed consent\n* Absence of solitary kidney status\n* No previous partial nephrectomy\u002Fies on the same kidney\n* Absence of preoperative chronic kidney disease (CKD) stage 5\n* Absence of any condition that makes mandatory or significantly more adequate the choice of a specific approach over the others (e.g., multiple previous major abdominal surgeries, horseshoe kidney, presence of stomas)",{"count":613,"type":22},124,[25],"This study aims to find out which surgical position is safer and works better for patients candidate to robot-assisted partial nephrectomy (RAPN) - a minimally invasive procedure to remove a small kidney tumor while preserving healthy kidney tissue.\n\nDuring this operation, the patient can be placed in two different positions:\n\n* the standard flank position, where the patient lies on their side\n* a newer supine position, where the patient lies on their back using a technique called Supine Anterior Retroperitoneal Approach (SARA).\n\nBoth approaches are performed using the Da Vinci® Single Port (SP) robotic system, a state-of-the-art surgical robot that allows the operation to be done through a single small incision.\n\nThe traditional flank position has been used for many years, but it can be uncomfortable for patients and may increase the risk of certain anesthetic or nerve-related complications, especially in people with higher body weight. The new supine SARA technique could make surgery faster, safer, and less painful, but it has not yet been tested in a randomized study.\n\nThis is the first clinical trial designed to directly compare these two approaches in patients with small and localized kidney cancers (tumors ≤7 cm, stage cT1).\n\nThe study will include 124 patients treated at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy - a leading center in robotic urologic surgery.",[617],"Kidney Neoplasm",[619,620,621,622,623],"kidney cancer","robotic surgery","single port","supine position","full flank position","2025-11-18",{"date":626,"type":38},"2025-11-21",{"date":628,"type":38},"2025-10-10",{"date":630,"type":22},"2027-03-30",{"name":44,"class":45},""]